For two companies the FDA PRO Guidance leads to similar but different measures

A case study in psoriasis

Mordin, M., Brown, T., McLeod, L., DeMuro, C., & Gnanasakthy, A. (2015). For two companies the FDA PRO Guidance leads to similar but different measures: A case study in psoriasis. Value in Health, 18(3), A111-A111. https://doi.org/10.1016/j.jval.2015.03.653

Abstract

The objective of this research is to evaluate whether the 2009 FDA PRO Guidance leads to development of similar measures when followed by different researchers in the same disease. Psoriasis was selected as a case study, because two companies recently published patient-reported outcome measures to assess the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) and the Psoriasis Symptom Diary (PSD).

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders
Article

Grandi Byen-supporting child growth and development through integrated, responsive parenting, nutrition and hygiene
Article

Effects of additional context information in prescription drug information sheets on comprehension and risk and efficacy perceptions
Article

"Show Me the Energy Costs"